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Inflammation and abnormalities in Toll-like receptor (TLR) expression and activation have been linked to
major depressive disorder (MDD). However, negative regulators of TLR pathways have not been previ-
ously investigated in this context. Here, we sought to investigate the association of depression severity,
measured by the 17-item Hamilton Depression Rating Scale (HAMD-17), with mRNA expression levels of
negative regulators of the TLR pathway, including SOCS1, TOLLIP, SIGIRR, MyD88s, NOD2 and TNFAIP3, in
peripheral blood mononuclear cells (PBMCs) from 100 patients with MDD and 53 healthy controls, before
and after treatment with antidepressants. Positive regulators of the TLR4 pathway, including Pellino 1,
TRAF6 and IRAK1, were also investigated. Among all patients, MyD88s, and TNFAIP3 mRNAs were
expressed at lower levels in PBMCs from patients with MDD. Multiple linear regression analyses revealed
that TNFAIP3 mRNA expression before treatment was inversely correlated with severity of depression
and effectively predicted improvement in HAMD-17 scores. Among 79 treatment-completers, only
TNFAIP3 mRNA was significantly increased by treatment with antidepressants for 4 weeks. Treatment
of human monocytes (THP-1) and mouse microglia (SIM-A9) cell lines with fluoxetine significantly
increased TNFAIP3 mRNA expression and suppressed IL-6 levels. The suppressive effect of fluoxetine
on IL-6 was attenuated by knockdown of TNFAIP3 expression. These findings suggest that both dysfunc-
tion of the negative regulatory system in patients with MDD and antidepressant treatment exert anti-
inflammatory effects, at least in part through increased expression of the TNFAIP3 gene. They also indicate
that modulating expression of the TNFAIP3 gene to rebalance TLR-mediated inflammatory signaling may
be potential therapeutic strategy for treating MDD.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major depressive disorder (MDD) represents a combination of
mood, anxiety, cognition, sleep, and appetite symptoms that last
for more than 2 weeks. MDD, which is responsible for 7.4% of total
disability-adjusted life years (DALYs) worldwide (Whiteford et al.,
2013), is highly associated with inflammation (Maes et al., 2015;Miller and Raison, 2016; Vogelzangs et al., 2014). One meta-
analysis reported elevated levels of pro-inflammatory cytokines,
including tumor necrosis factor (TNF)-a and interleukin (IL)-6, in
patents with MDD (Dowlati et al., 2010). Studies have also noted
that MDD is associated with increased monocyte numbers (Seidel
et al., 1996) and prostaglandin E2 secretion (Nishino et al., 1989).
The currently favored hypothesis is that pro-inflammatory
cytokines penetrate into the central nervous system and alter the
activity of indoleamine 2,3-dioxygenase (IDO), which activates
the kynurenine pathway and decreases the level of serotonin
(Haroon et al., 2012; Myint and Kim, 2014).
It has been reported that treatments for depression are associ-
ated with a reduction in inflammation. Selective serotonin
reuptake inhibitors (SSRIs) have been shown to diminish the
output of interferon-c (IFN-c) in whole blood stimulated with
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antidepressant of the SSRI class, have been shown to suppress
LPS-stimulated expression of IFN-c–inducible protein 10, also
known as C-X-C motif chemokine ligand 10 (CXCL10), in human
monocytes (Tsai et al., 2014). Fluoxetine was also demonstrated
to reduce LPS-induced pro-inflammatory IL-6 and TNF-a in human
peripheral blood mononuclear cells (PBMCs) (Waiskopf et al.,
2014). A variety of pathways, including the 5-HTT (5-hydroxy-
tryptamine transporter), nuclear factor-kappB (NF-jB), IL-10, and
cAMP have been investigated for their role in mediating the actions
of SSRIs (Walker, 2013). Fluoxetine was also shown to inhibit LPS-
induced decreases in intracellular acetylcholinesterase (AChE-S),
which interacts with NF-jB–activating intracellular RACK1 (recep-
tor for activated C kinase 1) (Waiskopf et al., 2014). However, the
specific molecular mechanisms by which antidepressants of the
SSRI class reduce inflammation have not yet been fully elucidated.
In terms of innate immune responses to MDD, recent studies
have demonstrated an association between activation of Toll-like
receptor (TLR)-4–mediated signaling and depression (Henry
et al., 2016; Hung et al., 2014). Clinical studies have shown that
TLR4 expression in the prefrontal cortex is enhanced in patients
with MDD (Garate et al., 2014). Altered peripheral expression of
TLRs appears to be associated with a heightened inflammatory
state and depression (Crupi and Cuzzocrea, 2016). In addition, clin-
ical studies have reported up-regulated TLR4 signaling in PBMCs in
patients with MDD (Hung et al., 2014). Notably, TLR4 was found to
be an independent risk factor for MDD severity and shown to be
associated with symptoms of depression, including body weight
loss and anxiety (Breese et al., 2008; Wu et al., 2015). We recently
reported that antidepressant treatment attenuated increases in
TLR4 mRNA associated with MDD (Hung et al., 2016), suggesting
a possible interaction between antidepressants and TLR4 signaling
pathways through an as yet unclear molecular mechanism(s).
Negative regulators of TLR4 signaling have been shown to inter-
sect almost every step of the TLR signaling pathway, serving to
protect against the potential harm of a prolonged, TLR-induced
cytokine storm by controlling the magnitude of the peak response
and/or duration of the response. IRAK3 (IL1 receptor-associated
kinase 3), SOCS1 (suppressor of cytokine signaling 1), MyD88s
(myeloid differentiation 88 short), TOLLIP (Toll-interacting
protein), TNFAIP3 (TNF a-induced protein 3), ST2L (suppressor
of tumorigenicity 2, full-length form), and SIGIRR (single
immunoglobulin IL-1R–related receptor) are among the negative
regulators of TLR-mediated immune responses (Liew et al., 2005).
One of these important negative regulators, TNFAIP3 (also known
as A20), acts as a deubiquitinase with specificity for lysine 63
(K63)-linked ubiquitin chains on TRAF6 (TNF receptor-associated
factor 6) to suppress NF-jB activation and inflammatory responses
(Shembade and Harhaj, 2012). While TNFAIP3 expression was
reported to be associated with bipolar disorder (Barzman et al.,
2014; Padmos et al., 2008), whether regulation of this negative
regulator of TLR-mediated signaling occurred in MDD patients
treated with antidepressants remains unknown.
Here, we investigated differences in the gene expression profile
of positive and negative regulators of TLR signaling in patients with
MDD and sought to determine possible anti-inflammatory mecha-
nisms underlying the actions of the antidepressant, fluoxetine.
2. Materials and methods
2.1. Experimental design
Inpatients with MDD were recruited from the psychiatric ward
of Kaohsiung Chang Gung Memorial Hospital, Taiwan, from August
2013 to May 2016. Blood samples for mRNA analysis were
obtained from patients before and after antidepressant treatment,and from 53 healthy controls at baseline. Institutional Review
Board approval was obtained from the hospital ethics committee
(101-5012A3, 103-5114B and 103-6984A3). After receiving verbal
and written information about the study, patients and healthy
controls provided written consent to participate.
2.2. Participants
Patients with MDD were screened by two psychiatrists before
entering the study. The screening steps, which were similar to
those described in our previous work (Hung et al., 2016), included
a Structured Clinical Interview for DSM-IV Axis I Disorders as well
as a detailed assessment of current psychiatric symptoms and
previous treatment. The 17-item Hamilton Depression Rating
Scale (HAMD-17) was used by the same psychiatrists to assess
the severity of depression. Patients with psychotic disorders,
substance dependence (including alcohol), severe metabolic
syndrome, severe obesity (body mass index [BMI] > 34 kg/m2) or
systemic inflammatory disease, or those who received antibiotics,
anti-inflammatory or immune-modulating drugs, were excluded
from the study. All patients were tested for blood pressure and
received chest X-rays, electrocardiographic examinations, and rou-
tine blood tests after hospitalization to exclude possible chronic
systemic physical illness. Enrolled patients reported no antidepres-
sant use for at least 1 week before entering the study. Healthy
controls, recruited from the community, had neither a personal
history nor a first-degree relative with a psychiatric disorder. The
same psychiatrist who performed screens of MDD patients
assessed the healthy control group using Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition) criteria to rule out
psychiatric disease.
After a clinical examination, blood samples were taken at two
time points: at inclusion (baseline) and 4 weeks after initiating
antidepressant treatment. Between these two time points, patients
were hospitalized in the psychiatric ward of Kaohsiung Chang
Gung Memorial Hospital with good drug adherence, regular
sleep-wake cycles, a well-controlled diet, and limited smoking.
2.3. Treatment
Treatment was administered as dictated by medical considera-
tions, meaning that the choice of treatment was not influenced by
the study and was chosen based on clinical judgment. After
screening at baseline, chosen antidepressants were administered
and recorded. The antidepressants included escitalopram
(10–20 mg/d; n = 14), fluoxetine (40–80 mg/d; n = 12), paroxetine
(20–40 mg/d; n = 12), sertraline (75 mg/d; n = 1) duloxetine
(60–120 mg/d; n = 25), venlafaxine (37.5–225 mg/d; n = 7), bupro-
pion (150–300 mg/d; n = 3), and agomelatine (25–50 mg/d; n = 5).
All patients were administered benzodiazepines as anxiolytics or
hypnotics, and had not received their medication for at least 8 h
prior to blood sampling. Supportive psychotherapy sessions were
provided one to two times, and regular activities were suggested
during hospitalization.
2.4. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) analysis
Venous blood (5 mL) samples were drawn between 8:00 am
and 10:00 am, after patients had fasted for 9 h. PBMCs were
isolated from venous blood samples by Ficoll-Paque (GE,
#17-5442-02) density gradient centrifugation. The isolated PBMCs
were labeled with BD IMag anti-human CD14 Magnetic Particles –
DM (BD Biosciences, #557769) according to the Magnetic Labeling
Protocol. The labeled fraction containing CD14(+) monocytes from
24 completers was collected for further analysis. The tubes were
Y.-Y. Hung et al. / Brain, Behavior, and Immunity 59 (2017) 265–272 267placed in a 80 C freezer immediately after collection and were
stored there until they were assayed. The protocol used for mRNA
analyses was the same as that used in our previous study (Hung
et al., 2016, 2014).
qRT-PCR was performed using the following sets of primers:
SOCS1 50-GAC CCC TTC TCA CCT CTT GA-30 (sense) and 50-GTA
GGA GGT GCG AGT TCA GG-30 (antisense); TOLLIP, 50-GAC AAC
TGT CTC CGT CGC A -30 (sense) and 50-CGG GAG CTC ACC GAT
GTA-30 (antisense); SIGIRR, 50-CCC AGC TCT TGG ATC AGT CT-30
(sense) and 50-AGT CAG GGG CCC TAT CAC AG-30 (antisense);
MyD88s, 50-TCA TCG AAA AGA GGT TGG CT-30(sense) and 50-GAT
GGG GAT CAG TCG CTT CT -30 (antisense); NOD2, 50- CGG CGT
TCC TCA GGA AGT AC-30 (sense) and 50-ACC CCG GGC TCA TGA
TG-30 (antisense); human TNFAIP3, 50-GGA CTT TGC GAA AGG
ATC G-30 (sense) and 50-TCA CAG CTT TCC GCA TAT TG-30 (anti-
sense); mouse TNFAIP3, 50-AAA CCA ATG GTG ATG GAA ACT G-30
(sense) and 50-GTT GTC CCA TTC GTC ATT CC-30 (antisense); ST2L,
50-CCC ACT CAG GAA AGA AAT CG-30 (sense) and 50-TTC GCA TAT
CCA GTC CTA TTG A-30 (antisense); IRAK3, 50-CTC GGT CAT CTG
TGG CAG TA -30 (sense) and 50-TTC TAG GTG GGA CCG GAA GT-30
(antisense); IRAK1, 50-TGC TAG AGA CCT TGG CTG GT-30 (sense)
and 50-GTG CTT CTC AAA GCC ACT CC-30 (antisense); TRAF6,
50-CTG TCC TTT GGC AAA TGT CA-30 (sense) and 50-TCA TGG CAA
CCA AAA GTA CTG-30 (antisense); Pellino1, 50-CCA AGC CTG GAA
TAT GGA GA-30 (sense) and 50-TGC TTC ACG GTA GGA GTG TG-30
(antisense); human IL-6, 50-GTA GCC GCC CCA CAC AGA-30 (sense)
and 50-CAT GTC TCC TTT CTC AGG GCT G-30 (antisense); mouse-18
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Fig. 1. Antidepressants directly increase the expression of TNFAIP3. (a) In monocytes iso
(n = 24), only the amount of TNFAIP3 was increased among all tested negative regulators.
line (b), an effect that was concentration dependent (c). (d, e) Fluoxetine significantly
knockdown of TNFAIP3 partially blocked the inhibitory effect of fluoxetine on IL-6 mRNA
cell line (b), an effect that was concentration dependent (c). (h, i) Fluoxetine has ma
siRNA-mediated knockdown of TNFAIP3 partially blocked the inhibitory effect of fluoxeIL-6, 50-TCC AGA AAC CGC TAT GAA GTT C-30 (sense) and 50-CAC
CAG CAT CAG TCC CAA GA-30 (antisense); human GAPDH, 50-TGC
ACC ACC AAC TGC TTA GC-30 (sense) and 50-GGC ATG GAC TGT
GGT CAT GAG-30 (antisense); and mouse GAPDH, 50-GCA CAG
TCA AGG CCG AGA AT-30 (sense) and 50-GCC TTC TCC ATG GTG
GTG AA-30 (antisense). Relative expression levels of target genes
in each sample were calculated based on the threshold cycle
(CT), where the difference in CT (DCT) used to represent relative
expression of clinical samples was defined as CTGAPDH  CTsample.
The 2DDCT method was used to calculate relative changes
in expression of target genes for cell assays, where
DDCT = DCTtreatment group  DCTcontrol group.
2.5. Cell culture
The THP-1 cell line was obtained from BCRC (Food Industry
Research and Development Institute, Taiwan) and maintained at
2  105 cells/mL in RPMI 1640 medium supplemented with
2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose,
10 mM HEPES, 1.0 mM sodium pyruvate, and 10% fetal bovine
serum (FBS). The SIM-A9 cell line was obtained from the American
Type Culture Collection (ATCC) and maintained in DMEM/F12 (Life
Technologies/GIBCO, Cat# 12400-016) containing 5% horse serum
and 10% FBS. All media contained 1.5 lg/mL penicillin/streptomy
cin/neomycin, and cells were incubated at 37 C in a humidified
5% CO2 atmosphere. In fluoxetine experiments, both cell types
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lated from PBMCs collected from patients before and after antidepressant treatment
(b, c) Fluoxetine significantly increased TNFAIP3 mRNA expression in the THP-1 cell
attenuated the LPS-induced increase in IL-6 mRNA expression. siRNA-mediated
(e). (f, g) Fluoxetine significantly increased TNFAIP3 mRNA expression in the SIM-A9
rginal effects in attenuating the LPS-induced increase in IL-6 mRNA expression.
tine on IL-6 mRNA (i). *p-value < 0.05, **p-value < 0.01.
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fluoxetine. After 1, 2, 6, 24 or 48 h, cells were harvested for further
analysis.
2.6. Transient transfection with siRNA
ON-TARGET plus SMARTpool small interfering RNA (siRNA)
against human TNFAIP3 (L-009919-00-0005) and ON-TARGETplus
non-targeting siRNA pool (D-001810-01) were purchased from
Dharmacon. The TransIT-X2 Dynamic Delivery System (Mirus,
#MIR 6000) was used for siRNA transfection, as described by the
manufacturer. In brief, THP-1 and SIM-A9 cells grown overnight
in 6-well plates were transfected with 30 nM TNFAIP3 siRNA or
control siRNA. Twenty-four hours after transfection, cells were
treated with 0.1 lM fluoxetine (Sigma, #F132) or control buffer
(Sigma, #F132) for an additional 24 h, and then incubated with
1 lg/mL LPS or phosphate-buffered saline (PBS) for 2 h and
harvested for further analysis.
2.7. Statistical analysis
All results are presented as means ± standard deviation. mRNA
levels shown in tables and Fig. 1a are presented as DCT; mRNA
levels in Fig. 1b–i are presented as 2DDCT. The chi-square test
was used to compare differences in demographic data (e.g., sex),
and Student’s t-test was used to compare differences in age and
BMI. A multivariate analysis of covariance (MANCOVA), adjusted
for age, sex, and body mass index (BMI), was used to compare
pre-treatment expression levels of negative regulators in patients
with MDDwith those in healthy controls (Table 2, I vs. III). A paired
t-test was used to compare differences in expression levels of neg-
ative regulators before and after antidepressant treatment (Table 2,
I vs. II). A linear regression model with forward selection was used
to establish the relationship between baseline mRNA levels of
negative regulators and baseline HAMD-17 scores (Table 3). A
linear regression model was also used to establish the relationship
between baseline mRNA levels of negative regulators and
decreases in HAMD-17 scores (Table 4). Student’s t-test was used
to compare differences in all cell line models. All statistical
analyses were performed using Statistical Product and Service
Solutions (SPSS), version 22. For each test, p-values <0.05 were
considered significant.
3. Results
3.1. Demographic and clinical characteristics of the study population
A total of 100 MDD patients were recruited (21 males and 79
females). Seventy-nine patients successfully completed a 4-week
antidepressant treatment. Among demographic variables, age
was significantly lower in the control group (39.75 ± 11.12 years)Table 1
Demographic findings and clinical data for healthy controls and MDD patients.
(1) (2)
MDD MDD
Pre-treatment Post-treatment
(n = 100) (n = 79)
Age (years) 45.69 ± 9.96 45.65 ± 9.92
Sex (M/F) 21/79 16/63
BMI (kg/m2) 24.02 ± 4.60 24.29 ± 4.82
Smoking 22 17
HAMD-17 26.87 ± 5.24 8.52 ± 5.75
Age, BMI: Student’s t-test.
Sex, Smoking: chi-square test.
* p-value < 0.05.
** p-value < 0.01.than in MDD patients before (45.69 ± 9.96 years) and after
(45.65 ± 9.92 years) treatment (Table 1). There was no significant
difference in BMI between healthy controls and MDD patients
before treatment, but the BMI in patients after treatment
(24.29 ± 4.82 kg/m2) was higher than that in the control group
(22.80 ± 3.05 kg/m2). HAMD-17 scores after treatment were
significantly reduced (8.52 ± 5.75) compared with baseline
(26.87 ± 5.24).
Gene expression profiling revealed a decrease in negative
regulators of TLR signaling in PBMCs from MDD patients that is
associated with severity of depression
To explore differences in the expression profile of positive and
negative regulators of TLR signaling between controls and MDD
patients, we first isolated PBMCs from enrolled individuals and
analyzed the mRNA expression of negative and positive regulators
of TLR signaling, including TNFAIP3, MyD88s, NOD2, SOCS1,
TOLLIP, SIGIRR, ST2L, IRAK3, IRAK1, TRAF6, TRAF6 and Pellino1.
Among all regulators, TNFAIP3 and MyD88s were significantly
decreased in PBMCs isolated from MDD patients at baseline
compared with healthy controls, based on age-, sex-, and BMI-
adjusted MANCOVAs. No significant differences were found for
NOD2, SOCS1, TOLLIP, SIGIRR, ST2L or IRAK3, or for the positive
regulators of TLR signaling, Pellino 1, TRAF6, and IRAK1. Compar-
isons of baseline expression of negative regulators between MDD
patients and healthy controls are summarized in Table 2 (I vs.
III). The clinical association of the expression of negative regulators
with severity of depression was assessed using a linear regression
analysis, which showed that only TNFAIP3 levels were negatively
correlated with HAMD-17 scores (r = 0.207, p = 0.046; Table 3).
3.2. TNFAIP3 expression is increased in MDD patients after
antidepressant treatment and serves as a predictive factor for
antidepressant response
To evaluate the association between antidepressant treatment
and negative regulators of TLR signaling, we reassessed the 79
patients who completed the 4 weeks of therapy. Only TNFAIP3
mRNA expression in PBMCs was significantly increased after
4 weeks of therapy compared with baseline (Table 2, I vs. II). To
further investigate the association between antidepressant treat-
ment and negative regulators of TLR signaling, we performed a lin-
ear regression analysis, which showed that TNFAIP3 (r = 0.269,
p = 0.024) and ST2L (r = 0.248, p = 0.036) levels were predictive of
decreases in HAMD-17 scores among the 79 completers (Table 4).
3.3. TNFAIP3 expression is significantly increased in MDD patients
treated with SSRI antidepressants
Among the 79 patients who received 4-week antidepressant
treatment, 39 received SSRIs, whereas 31 received a serotonin–nor
epinephrine reuptake inhibitor (SNRI). The other nine patients(3) p-value
Healthy
controls (1) vs. (3) (2) vs. (3)
(n = 53)
39.75 ± 11.12 0.001** 0.002**
15/38 0.313 0.287
22.80 ± 3.05 0.055 0.033*
6 0.105 0.131
– – –
Table 2
mRNA expression levels (DCt) of negative regulators in healthy controls and patients with MDD.
MDD III. Healthy controls F-, T- and p-values
I. Pre-treatment II. Post-treatment I vs. III I vs. II
SOCS1 5.28 ± 1.55 5.31 ± 1.26 5.23 ± 1.10 F = 0.690 T = 1.163
p = 0.408 p = 0.247
TOLLIP 10.58 ± 1.95 10.90 ± 2.12 9.94 ± 2.39 F = 1.826 T = 1.078
p = 0.179 p = 0.283
SIGIRR 4.32 ± 1.68 4.43 ± 1.59 4.27 ± 1.59 F = 0.927 T = 1.139
p = 0.337 p = 0.257
MyD88s 6.48 ± 0.90 6.43 ± 0.80 6.10 ± 0.77 F = 8.584 T = 0.668
p = 0.004** p = 0.505
NOD2 6.33 ± 1.35 6.44 ± 1.50 5.89 ± 1.69 F = 2.673 T = 0.576
p = 0.104 p = 0.566
TNFAIP3 6.05 ± 1.39 5.32 ± 0.89 5.61 ± 0.69 F = 5.752 T = 4.173
p = 0.018* p = 0.000**
ST2L 9.76 ± 2.49 10.06 ± 1.96 9.38 ± 1.59 F = 1.425 T = 0.496
p = 0.235 p = 0.620
IRAK3 5.87 ± 1.64 5.65 ± 0.89 5.57 ± 0.61 F = 0.010 T = 1.039
p = 0.920 p = 0.301
IRAK1 6.27 ± 1.01 6.33 ± 0.81 6.23 ± 0.62 F = 0.010 T = 0.469
p = 0.921 p = 0.640
TRAF6 7.02 ± 1.27 7.24 ± 1.36 7.08 ± 0.87 F = 0.573 T = 0.530
p = 0.450 p = 0.598
Pellino1 4.37 ± 1.68 4.65 ± 1.34 4.53 ± 1.83 F = 1.416 T = 0.099
p = 0.236 p = 0.921
IL6 8.49 ± 1.84 8.71 ± 1.87 9.24 ± 1.64 F = 4.365 T = 2.927
p = 0.038* p = 0.004**
I vs. II: Paired t-test.
I vs. III: age, sex, BMI-adjusted multivariate analysis of covariance.
GAPDH was used as a housekeeping gene to assess the relative abundance of mRNA.
* p-value < 0.05.
** p-value < 0.01
Table 3
Relationship between baseline mRNA levels of negative regulators and baseline
HAMD-17 scores.
Independent factors HAMD-17 score
Standardized coefficients t p-value
SOCS1 0.022 0.215 0.830
TOLLIP 0.128 0.841 0.403
SIGIRR 0.025 0.226 0.821
MyD88s 0.073 0.641 0.523
NOD2 0.199 1.946 0.055
TNFAIP3 0.207 2.024 0.046*
ST2 0.046 0.841 0.403
IRAK3 0.108 1.108 0.283
Linear regression with forward-to-remove was used to analyze the association
between negative regulators and severity of depression.
* p-value < 0.05.
Table 4
Relationship between baseline mRNA levels of negative regulators and decreases in
HAMD-17 scores.
Independent factors HAMD-17 score change
Standardized coefficients T p-value
SOCS1 0.078 0.661 0.511
TOLLIP 0.099 0.806 0.423
SIGIRR 0.072 0.581 0.563
MyD88s 0.045 0.329 0.743
NOD2 0.050 0.412 0.681
TNFAIP3 0.269 2.312 0.024*
ST2L 0.248 2.131 0.036*
IRAK3 0.044 0.374 0.709
Linear regression with forward-to-remove was used to analyze the association
between negative regulators and severity of depression.
* p-value < 0.05.
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nificantly increased TNFAIP3 mRNA levels in PBMCs, whereas
SNRIs treatment was associated with a trend towards increased
TNFAIP3 expression that did not reach statistical significance. SSRIs
also increased MyD88s and NOD2 mRNA expression, whereas
SNRIs decreased TOLLIP expression (Table 5).3.4. Fluoxetine induces TNFAIP3 expression in monocytes and
microglia cells
We next isolated monocytes from PBMCs and examined mRNA
expression profiles of negative regulators. Similar to the results
obtained from PBMCs, TNFAIP3 mRNA levels were significantly
increased in monocytes from MDD patients after antidepressant
treatment (Fig. 1a). To further examine the potential effects of
fluoxetine, an antidepressant of the SSRI class, on the expression
of TNFAIP3 mRNA in monocytes and microglia, we pretreated
THP-1 cells, a monocyte cell line, and SIM-A9 cells, a microglia cell
line, for varying durations with different concentrations (107 to
105 M) of fluoxetine. Treatment with fluoxetine for 2 h induced
an increase in TNFAIP3 mRNA expression in THP-1 and SIM-A9
cells (p < 0.05, Fig. 1b and f), an effect that was concentration
dependent (Fig. 1c and g).3.5. TNFAIP3 is required for suppression of IL-6 expression by
fluoxetine
To examine the mechanism by which fluoxetine suppresses the
expression of IL-6, we first transfected THP-1 and SIM-A9 cells
with siRNA targeting TNFAIP3 for 24 h and then treated cells with
fluoxetine (105 M) for 24 h to induce TNFAIP3. After pretreatment,
THP-1 and SIM-A9 cells were treated with LPS to stimulate the pro-
duction of IL-6. The suppressive effect of fluoxetine on LPS-induced
Table 5
Comparison of mRNA expression levels (-DCt) of negative regulators in MDD patients before and after two different antidepressant treatments.
SSRIs (n = 39) p-value SNRIs (n = 32) p-value
Pre-treatment Post-treatment Pre-treatment Post-treatment
SOCS1 4.79 ± 1.54 4.80 ± 1.30 p = 0.967 5.70 ± 1.47 5.86 ± 0.95 p = 0.239
TOLLIP 10.27 ± 1.64 10.08 ± 1.65 p = 0.530 11.56 ± 1.75 11.93 ± 2.23 p = 0.042*
SIGIRR 4.11 ± 1.59 4.09 ± 1.43 p = 0.665 4.55 ± 1.93 4.81 ± 1.70 p = 0.112
MyD88s 6.85 ± 1.00 6.57 ± 0.73 p = 0.028* 6.04 ± 0.70 6.20 ± 0.72 p = 0.304
NOD2 6.37 ± 1.05 6.00 ± 1.36 p = 0.004* 6.75 ± 1.43 7.03 ± 1.53 p = 0.140
TNFAIP3 6.33 ± 1.01 5.32 ± 0.82 p = 0.000** 5.96 ± 1.91 5.20 ± 0.95 p = 0.052
ST2L 10.53 ± 1.86 10.09 ± 2.45 p = 0.081 9.76 ± 2.80 9.94 ± 1.09 p = 0.640
IRAK3 5.91 ± 1.54 5.80 ± 1.15 p = 0.521 5.70 ± 1.81 5.47 ± 0.44 p = 0.736
A paired sample t-test was used to compare differences between pre- and post-treatment.
GAPDH was used as a housekeeping gene to assess the relative abundance of mRNA.
SSRIs, selective serotonin reuptake inhibitors; SNRIs, Serotonin–norepinephrine reuptake inhibitors.
* p-value < 0.05.
** p-value < 0.01.
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siRNA-mediated knockdown of TNFAIP3 (Fig. 1e and i).4. Discussion
In this study, we demonstrated significant changes in negative
regulators of the TLR-mediated inflammatory pathway in acute
MDD patients, showing that, prior to antidepressant treatment,
TNFAIP3 and MyD88s expression were lower in PBMCs from
MDD patients than in healthy controls. These results suggest an
imbalance in the TLR-mediated inflammatory pathway in MDD.
Moreover, we found that antidepressant treatment significantly
increased TNFAIP3 expression both in vivo and in vitro, and this
is the first report to suggest the involvement of TNFAIP3 in the
mechanism by which antidepressants may reduce inflammation
in MDD patients.
SSRIs have long been reported to exert anti-inflammatory
effects (Ohgi et al., 2013; Tynan et al., 2012) and effectively mod-
ulate inflammatory diseases (Branco-de-Almeida et al., 2012; Koh
et al., 2011). SSRIs, including paroxetine and fluoxetine, were
recently reported to reduce IL-6 secretion through inhibition of
LPS-induced IjBa phosphorylation rather than through actions at
the 5-HT receptor (Durairaj et al., 2015). Our results support these
finding, showing that TNFAIP3 is required for suppression of
LPS-mediated IL-6 expression by fluoxetine. In addition, both SNRIs
and SSRIs exerted similar effects on the serotonin transporter, but
only SSRIs significantly increased TNFAIP3 expression (Table 5),
further highlighting the fact that neither 5-HT receptors nor sero-
tonin transporters are involved in the anti-inflammatory response
to fluoxetine. Together, our study may provide novel evidence of
unique peripheral mechanisms by which fluoxetine may reduce
inflammation, which may be more associated with response than
its effects on serotonin, which should be equally changed by SNRIs.
Furthermore, our analysis of clinical outcomes revealed that lower
expression of TNFAIP3 in patients before antidepressant treatment
predicted greater improvement in HAMD scores after antidepres-
sant treatment (Table 4), suggesting that clinical responses are
associated with antidepressants and TNFAIP3.
Interestingly, the current study found that low TNFAIP3 levels
were passively correlated with pretreatment HAMD scores. To
our knowledge, this is the first study to report an association
between clinical severity in MDD and expression of the TNFAIP3
gene. Reducing TNFAIP3 expression would cause excessive produc-
tion of pro-inflammatory cytokines, including TNF-a and IL-6
(Guedes et al., 2014). IL-6, in turn, has been shown to reduce
5-HT levels through activation of the tryptophan-metabolizing
enzyme, IDO (Myint and Kim, 2014). Our findings strengthen theconcept that dysregulation of TLR signaling is causally linked to
major depression.
TNFAIP3 has attracted considerable attention by virtue of its
role in autoimmune diseases, including systemic lupus erythe-
matosus (SLE) (Han et al., 2016) and rheumatic arthritis (RA)
(Ruiz-Larranaga et al., 2016). A case report noted depression as
an initial feature of SLE (Marian et al., 2010). The prevalence of
depression is also significantly higher in SLE patients compared
with the general population, but the severity of depression is
independent of SLE disease characteristics (van Exel et al., 2013).
In addition, increased levels of TNFAIP3 have been shown to ame-
liorate disease progression in an animal model of RA (Vande Walle
et al., 2014). Interestingly, SSRIs have been shown to significantly
inhibit the spontaneous production of TNF, IL-6, and CXCL10 in
human RA synovial membrane cultures (Sacre et al., 2010) and
was reported to be as effective as methotrexate, the first-line
treatment for RA patients (Baharav et al., 2012). The efficacy of
methotrexate monotherapy for arthritis is associated with TNFAIP3
(Plant et al., 2012). In light of the involvement of SSRI effectiveness
in MDD and RA, the use of methotrexate in MDD patients with low
TNFAIP3 status warrants further investigation.
The mechanisms underlying the effects of negative regulators of
TLR-mediated inflammatory signaling, especially TNFAIP3, on the
psychopathology of depression are largely unknown. There is
some evidence linking TNFAIP3-mediated inhibition of the
activation of the NLRP3 inflammasome, which mediates innate
immune system activation, with the susceptibility to depression-
like behavior (Alcocer-Gomez et al., 2016; Cheng et al., 2016). A
TNFAIP3 deficiency in macrophages significantly enhances NLRP3
inflammasome-mediated caspase-1 activation, pyroptosis, and
interleukin-1b secretion (Vande Walle et al., 2014) by restricting
ubiquitination of pro-interleukin-1b protein complexes (Duong
et al., 2015). On the other hand, TNFAIP3 overexpression signifi-
cantly alleviates inflammatory responses and reduces activation
of NF-jB and the NLRP3 inflammasome (Li et al., 2015). Taken
together, these results support our concept that TNFAIP3 is a
potentially important target in the treatment of MDD. In addition,
there is also some evidence suggesting that TNFAIP3 is associated
with neurodegeneration. TNFAIP3 targets the TNF apoptotic path-
way by inhibiting proteolytic cleavage of caspase-8 and -3; it can
also effectively protect the SH-SY5Y neuronal cell line from apop-
tosis (Yu et al., 2006). RNF11 (RING finger protein 11), in associa-
tion with the TNFAIP3 ubiquitin-editing complex, is a key
negative regulator of NF-jB and has been suggested as a negative
regulator of neurodegeneration in a microglia cell line (Dalal et al.,
2012). TNFAIP3-knockout mice display a remarkable degree of
reactive microgliosis and astrogliosis (Guedes et al., 2014), and
mice with selective deletion of TNFAIP3 in astrocytes exhibit
Y.-Y. Hung et al. / Brain, Behavior, and Immunity 59 (2017) 265–272 271demyelination owing to NF-jB and STAT1 hyperactivation (Wang
et al., 2013). These data support an important role for TNFAIP3 in
neuronal homeostasis (Pranski et al., 2012).
This study has several limitations. One limitation is the absence
of a healthy control group exposed to the same environment. The
interactions among antidepressants, cytokines, and negative regu-
lators will require further controlled studies. Moreover, treatment
was not randomized, so it is possible that clinical factors that
determined treatment might have influenced results. Finally, the
sample size of the control group in the current study is relatively
small, and washout periods of antidepressants before collecting
baseline samples may be insufficient. Further analyses using larger
sample sizes and longer washout period are needed to confirm
these results.
Although the analysis conducted in our current study may be
limited, this report is nonetheless the first to link negative
regulators of the TLR pathway, in particular TNFAIP3, with MDD.
The therapeutic implications of our findings are considerable. In
conjunction with current therapeutic regimens, modulating
expression of the TNFAIP3 gene to rebalance TLR-mediated inflam-
matory signaling may provide a potential approach for MDD
management.
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